{"id":56762,"date":"2025-08-25T13:14:49","date_gmt":"2025-08-25T11:14:49","guid":{"rendered":"https:\/\/www.fyb.de\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/"},"modified":"2025-09-03T13:15:17","modified_gmt":"2025-09-03T11:15:17","slug":"ypog-advises-investors-on-e-21-million-round-for-evlabio","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/","title":{"rendered":"YPOG advises investors on \u20ac 21 million round for EvlaBio"},"content":{"rendered":"<p>D\u00fcsseldorf\/ Zurich (CH) \/ Berlin \u2014 YPOG advi\u00adsed a consor\u00adtium of inves\u00adtors led by Kurma Part\u00adners on the EUR 21 million finan\u00adcing round of the biotech company Evla\u00adBio. The finan\u00adcing round was led by Kurma Part\u00adners, toge\u00adther with Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund, AdBio Part\u00adners, HTGF and NRW.BANK. <\/p>\n<p>With the new funds, Evla\u00adBio will advance the deve\u00adlo\u00adp\u00adment of its lead candi\u00addate \u2014 a novel mono\u00adclonal anti\u00adbody targe\u00adting the FGF23\/FGFR4 signal\u00ading cascade, a key driver of cardiac remo\u00adde\u00adling in pati\u00adents with chro\u00adnic kidney dise\u00adase (CKD). The therapy speci\u00adfi\u00adcally targets the treat\u00adment of left ventri\u00adcu\u00adlar hyper\u00adtro\u00adphy, a common and severe compli\u00adca\u00adtion of&nbsp;CKD.&nbsp;<\/p>\n<p><strong>Hadrien Bouchez <\/strong>(photo \u00a9 Kurma), <strong>Part\u00adner at Kurma Part\u00adners<\/strong>: \u201cThe team\u2019s precli\u00adni\u00adcal data and scien\u00adti\u00adfic foun\u00adda\u00adtion are impres\u00adsive. Evla\u00adBio addres\u00adses a highly rele\u00advant medi\u00adcal need that has not yet been adequa\u00adtely addressed.\u201d&nbsp;<\/p>\n<p><strong>Evla\u00adBio<\/strong> is a life science company focu\u00adsed on the deve\u00adlo\u00adp\u00adment of first-in-class thera\u00adpeu\u00adtics for cardio\u00advas\u00adcu\u00adlar and cardio\u00adre\u00adnal dise\u00ada\u00adses. The lead program addres\u00adses the FGFR4\/FGF23 signal\u00ading cascade, which is a key driver of cardiac remo\u00adde\u00adling in chro\u00adnic kidney dise\u00adase. By deve\u00adlo\u00adping novel mecha\u00adnisms based on sound science, Evla\u00adBio aims to create new treat\u00adment para\u00addigms for CKD pati\u00adents with high unmet medi\u00adcal&nbsp;need.&nbsp;<\/p>\n<p>Our colle\u00adagues at Walder Wyss supported the inves\u00adtor consor\u00adtium on Swiss legal and tax issues.<\/p>\n<p><strong>Advi\u00adsor to the inves\u00adtor consor\u00adtium:&nbsp;YPOG<br>\n<\/strong><br>\n Dr. Martin Scha\u00adper (Tran\u00adsac\u00adtions), Part\u00adner, Berlin<br>\nJ\u00f6rg Schr\u00adade (Tax), Part\u00adner, Munich<br>\nDr. Bene\u00addikt Fl\u00f6ter (IP\/IT\/Data Protec\u00adtion), Part\u00adner, Hamburg<br>\nCiro D\u2019Ame\u00adlio (Tran\u00adsac\u00adtions), Asso\u00adciate, Berlin<br>\nChris\u00adtoph Cordes (IP\/IT\/Data Protec\u00adtion), Asso\u00adciate, Berlin<br>\nBoris Schin\u00adzel (Tran\u00adsac\u00adtions), Asso\u00adciate, Berlin<br>\nNinetta Klein\u00addienst (Tax), Asso\u00adciate, Munich<\/p>\n<p>www.ypog.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>D\u00fcsseldorf\/ Zurich (CH) \/ Berlin \u2014 YPOG advi\u00adsed a consor\u00adtium of inves\u00adtors led by Kurma Part\u00adners on the EUR 21 million finan\u00adcing round of the biotech company Evla\u00adBio. The finan\u00adcing round was led by Kurma Part\u00adners, toge\u00adther with Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund, AdBio Part\u00adners, HTGF and NRW.BANK. With the new funds, Evla\u00adBio will advance the&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":56760,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1366],"tags":[],"class_list":["post-56762","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>YPOG advises investors on \u20ac 21 million round for EvlaBio - FYB Financial Yearbook<\/title>\n<meta name=\"description\" content=\"D\u00fcsseldorf\/ Zurich (CH) \/ Berlin - YPOG advised a consortium of investors led by Kurma Partners on the EUR 21 million financing round of the biotech company EvlaBio. The financing round was led by Kurma Partners, together with Boehringer Ingelheim Venture Fund, AdBio Partners, HTGF and NRW.BANK.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"YPOG advises investors on \u20ac 21 million round for EvlaBio - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"D\u00fcsseldorf\/ Zurich (CH) \/ Berlin - YPOG advised a consortium of investors led by Kurma Partners on the EUR 21 million financing round of the biotech company EvlaBio. The financing round was led by Kurma Partners, together with Boehringer Ingelheim Venture Fund, AdBio Partners, HTGF and NRW.BANK.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T11:14:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-03T11:15:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/09\/kurma-dr-hadrien-bouchez-kurma.png\" \/>\n\t<meta property=\"og:image:width\" content=\"680\" \/>\n\t<meta property=\"og:image:height\" content=\"796\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"YPOG advises investors on \u20ac 21 million round for EvlaBio\",\"datePublished\":\"2025-08-25T11:14:49+00:00\",\"dateModified\":\"2025-09-03T11:15:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/\"},\"wordCount\":273,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/09\/kurma-dr-hadrien-bouchez-kurma.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/\",\"url\":\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/\",\"name\":\"YPOG advises investors on \u20ac 21 million round for EvlaBio - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/09\/kurma-dr-hadrien-bouchez-kurma.png\",\"datePublished\":\"2025-08-25T11:14:49+00:00\",\"dateModified\":\"2025-09-03T11:15:17+00:00\",\"description\":\"D\u00fcsseldorf\/ Zurich (CH) \/ Berlin - YPOG advised a consortium of investors led by Kurma Partners on the EUR 21 million financing round of the biotech company EvlaBio. The financing round was led by Kurma Partners, together with Boehringer Ingelheim Venture Fund, AdBio Partners, HTGF and NRW.BANK.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/09\/kurma-dr-hadrien-bouchez-kurma.png\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/09\/kurma-dr-hadrien-bouchez-kurma.png\",\"width\":680,\"height\":796,\"caption\":\"Dr. Hadrien Bouchez, Partner bei Kurma Partners (\u00a9 Kurma)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"YPOG advises investors on \u20ac 21 million round for EvlaBio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"YPOG advises investors on \u20ac 21 million round for EvlaBio - FYB Financial Yearbook","description":"D\u00fcsseldorf\/ Zurich (CH) \/ Berlin - YPOG advised a consortium of investors led by Kurma Partners on the EUR 21 million financing round of the biotech company EvlaBio. The financing round was led by Kurma Partners, together with Boehringer Ingelheim Venture Fund, AdBio Partners, HTGF and NRW.BANK.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/","og_locale":"en_US","og_type":"article","og_title":"YPOG advises investors on \u20ac 21 million round for EvlaBio - FYB Financial Yearbook","og_description":"D\u00fcsseldorf\/ Zurich (CH) \/ Berlin - YPOG advised a consortium of investors led by Kurma Partners on the EUR 21 million financing round of the biotech company EvlaBio. The financing round was led by Kurma Partners, together with Boehringer Ingelheim Venture Fund, AdBio Partners, HTGF and NRW.BANK.","og_url":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2025-08-25T11:14:49+00:00","article_modified_time":"2025-09-03T11:15:17+00:00","og_image":[{"width":680,"height":796,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/09\/kurma-dr-hadrien-bouchez-kurma.png","type":"image\/png"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"YPOG advises investors on \u20ac 21 million round for EvlaBio","datePublished":"2025-08-25T11:14:49+00:00","dateModified":"2025-09-03T11:15:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/"},"wordCount":273,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/09\/kurma-dr-hadrien-bouchez-kurma.png","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/","url":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/","name":"YPOG advises investors on \u20ac 21 million round for EvlaBio - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/09\/kurma-dr-hadrien-bouchez-kurma.png","datePublished":"2025-08-25T11:14:49+00:00","dateModified":"2025-09-03T11:15:17+00:00","description":"D\u00fcsseldorf\/ Zurich (CH) \/ Berlin - YPOG advised a consortium of investors led by Kurma Partners on the EUR 21 million financing round of the biotech company EvlaBio. The financing round was led by Kurma Partners, together with Boehringer Ingelheim Venture Fund, AdBio Partners, HTGF and NRW.BANK.","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/09\/kurma-dr-hadrien-bouchez-kurma.png","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/09\/kurma-dr-hadrien-bouchez-kurma.png","width":680,"height":796,"caption":"Dr. Hadrien Bouchez, Partner bei Kurma Partners (\u00a9 Kurma)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/ypog-advises-investors-on-e-21-million-round-for-evlabio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"YPOG advises investors on \u20ac 21 million round for EvlaBio"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/56762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=56762"}],"version-history":[{"count":1,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/56762\/revisions"}],"predecessor-version":[{"id":56763,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/56762\/revisions\/56763"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/56760"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=56762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=56762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=56762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}